SUPRIYA has built a durable and defensible margin moat, consistently delivering 30–35% EBITDA, well above Indian API peers (mid-20s). This structural edge is driven by two entrenched strengths: Deep backward integration: ~18 integrated products contribute 81% of Q1FY26 revenue, buffering the business from input volatility and ensuring stable realizations. Dominance in niche therapies: Leadership in anesthetics and anti-anxiety APIs—markets with limited domestic competition support premium pricing power. Margins are expected to temporarily soften to ~33% in FY26E due to Ambernath scale-up costs. However, we believe EBITDA margin is positioned to normalise at ~35% by FY28E, sustaining structural leadership.
OutlookWe forecast Revenue/EBITDA/PAT CAGR of 21.6%/18.9%/19.4% over FY25–28E, driven by operating leverage and a richer mix of complex, higher-value products. With contracted revenue visibility, we value the business using DCF method (click here to view). With a TP of INR 1,030 and a 38.6% upside, we initiate our coverage with a BUY rating on the stock. This results in an implied PE of 29x, broadly in line with peers with a PEG ratio of 1.5x.
For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Supriya Lifescience - 12112025 - choiceDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
